LONDON (Alliance News) - Akers Biosciences Inc on Thursday said its rapid chlamydia test clinical trial had been "highly successful", with both high sensitivity and specificity ratings, which it said "bodes well" not only for this test, but for its other products as well.
The biotechnology company said the clinical trial of its Particle ImmunoFiltration Assay/Chlamydia Rapid Assay was carried out across two sites in Pennsylvania, in the US, and produced a sensitivity level of 91% and a specificity level of 98%. This was a "highly successful" outcome, Akers said.
The overall agreement between the PIFA/Chlamydia Rapid Assay and the reference laboratory method was 96% in patient populations of acute infection and historical exposure, Akers added.
Akers's rapid chlamydia test is an antibody test which can identify the chlamydia infection in five minutes or less from a finger blood stick sample, reducing the waiting time from the current typical level of ten days.
The test uses Akers's Particle ImmunoFiltration Assay, also used in a number of other tests under development as well as Akers's flagship PIFA/Heparin Platelet Factor 4 Rapid Assay, used to test whether patients have heparin induced thrombocytopenia, an immune disease.
"We are delighted with the outcome of these clinical trial results. The test performed extremely well, with a 96% correlation to the gold standard reference laboratory method. It is a very exciting outcome to have a five-minute rapid test demonstrate that level of accuracy. This bodes well not only for the PIFA/Chlamydia Rapid Assay but for our other proprietary PIFA technology based tests in development," said Co-Founder and Chief Scientific Director Raymond Akers.
Shares in Akers were up 18% at 200.00 pence on Thursday.
By Hannah Boland; hannahboland@alliancenews.com; @Hannaheboland
Copyright 2016 Alliance News Limited. All Rights Reserved.
